A detailed history of China Universal Asset Management Co., Ltd. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 26,280 shares of VIR stock, worth $227,059. This represents 0.02% of its overall portfolio holdings.

Number of Shares
26,280
Previous 15,986 64.39%
Holding current value
$227,059
Previous $142,000 38.03%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$7.26 - $10.7 $74,734 - $110,145
10,294 Added 64.39%
26,280 $196,000
Q2 2024

Jul 19, 2024

SELL
$7.63 - $12.66 $76,208 - $126,448
-9,988 Reduced 38.45%
15,986 $142,000
Q1 2024

Apr 29, 2024

BUY
$8.6 - $11.9 $89,560 - $123,926
10,414 Added 66.93%
25,974 $263,000
Q4 2023

May 21, 2024

SELL
$7.76 - $10.29 $80,812 - $107,160
-10,414 Reduced 40.09%
15,560 $156,000
Q4 2023

Jan 23, 2024

BUY
$7.76 - $10.29 $93,989 - $124,632
12,112 Added 351.28%
15,560 $157,000
Q3 2023

May 21, 2024

BUY
$9.14 - $24.62 $15,464 - $41,657
1,692 Added 96.36%
3,448 $32,000
Q3 2023

Oct 30, 2023

BUY
$9.14 - $24.62 $15,464 - $41,657
1,692 Added 96.36%
3,448 $32,000
Q2 2023

May 21, 2024

SELL
$23.2 - $27.29 $1,229 - $1,446
-53 Reduced 2.93%
1,756 $43,000
Q2 2023

Jul 27, 2023

SELL
$23.2 - $27.29 $1,229 - $1,446
-53 Reduced 2.93%
1,756 $43,000
Q1 2023

May 21, 2024

BUY
$22.26 - $30.85 $10,150 - $14,067
456 Added 33.7%
1,809 $42,000
Q1 2023

Apr 27, 2023

BUY
$22.26 - $30.85 $10,150 - $14,067
456 Added 33.7%
1,809 $42,000
Q4 2022

May 21, 2024

SELL
$19.96 - $28.22 $491,435 - $694,804
-24,621 Reduced 94.79%
1,353 $34,000
Q4 2022

Jan 31, 2023

BUY
$19.96 - $28.22 $2,215 - $3,132
111 Added 8.94%
1,353 $34,000
Q3 2022

Oct 21, 2022

BUY
$18.26 - $31.1 $22,678 - $38,626
1,242 New
1,242 $24,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.15B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.